20,789 reports of this reaction
2.7% of all DUPILUMAB reports
#9 most reported adverse reaction
PRODUCT DOSE OMISSION ISSUE is the #9 most commonly reported adverse reaction for DUPILUMAB, manufactured by sanofi-aventis U.S. LLC. There are 20,789 FDA adverse event reports linking DUPILUMAB to PRODUCT DOSE OMISSION ISSUE. This represents approximately 2.7% of all 782,562 adverse event reports for this drug.
Patients taking DUPILUMAB who experience product dose omission issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION ISSUE is a less commonly reported adverse event for DUPILUMAB, but still significant enough to appear in the safety profile.
In addition to product dose omission issue, the following adverse reactions have been reported for DUPILUMAB:
The following drugs have also been linked to product dose omission issue in FDA adverse event reports:
PRODUCT DOSE OMISSION ISSUE has been reported as an adverse event in 20,789 FDA reports for DUPILUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION ISSUE accounts for approximately 2.7% of all adverse event reports for DUPILUMAB, making it a notable side effect.
If you experience product dose omission issue while taking DUPILUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.